Investment Thesis
- As the Covid pandemic subsides, near-term earnings may underwhelm but longer term, we don’t doubt the quality of SHL’s assets, which is geographically diversified, and high quality management team.
- Ageing population requires more diagnostic tests, especially as Medicine focuses on preventative medicine.
- Market leading positions in pathology (number one in Australia, Germany, Switzerland, and UK number three in the US). Second leading player in Imaging in Australia.
- High barriers to entry in establishing global channels.
- Ongoing bolt-on acquisitions to supplement organic growth and potentially improve margin from cost synergies.
- Leveraged to a falling dollar.
- Globally diversified.
Key Risks
- Disruptive technology leading to reduced diagnostics costs.
- Competitive threats leading market share loss.
- Deregulation resulting in new pathology collection centres.
- Adverse regulatory changes (fee cuts).
- Disappointing growth.
- Adverse currency movements (AUD, EUR, USD).
Bulls Say’s
- Revenue of $4,757m, up +7%.
- EBITDA of $1,540m, up +18%.
- Net Profit of $828m, up +22%.
- Cash generated from operations of $1,041m, up +28%, reflecting EBITDA growth and lower interest payments. SHL achieved 85% conversion of EBITDA to gross operating cash flow.
- Earnings per share of 170.8cps, up +21%.
- SHL retained a strong balance sheet position, with gearing at record low level of 12.9% (vs 12.5% in the pcp) and below covenant at <55%, interest cover of 44.9x (vs 33.8x in the pcp and above covenant limit of >3.25x) and debt cover of 0.3x (vs 0.4x in the pcp and covenant limit of <3.5x), and with ~$1.4bn of available liquidity.
- SHL maintained its progressive dividend policy, with the Board declaring an increase of 4 cents (or up +11%) to 40 cents (100% franked) for the FY2022 Interim Dividend.
Company Profile
Sonic Healthcare (SHL) is a medical diagnostics company with operations in Australia, New Zealand, and Europe. The company provides a comprehensive range of pathology and diagnostic imaging services to medical practitioners, hospitals and their patients along with providing administrative services and facilities to medical practitioners. SHL has three main segments: (1) Pathology/clinical laboratory services based in Australia, NZ, UK, US, Germany, Switzerland, Belgium and Ireland. (2) Diagnostic imaging services in Australia; and (3) Other which includes medical centre operations (IPN), occupational health services (Sonic HealthPlus) and laboratory automation development (GLP Systems).
(Source: BanyanTree)
General Advice Warning
Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.